{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:59:58Z","timestamp":1788274798302,"version":"build-2803163510"},"reference-count":119,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Uveal melanoma is the most common primary intraocular malignancy in adults, with distinct genetic and clinical characteristics compared with cutaneous melanoma. Despite improvements in the treatment of the primary tumour, nearly half of the patients will develop distant metastases, most commonly in the liver. Once metastases are detected, the median overall survival is approximately 1 year, with a 2-year survival rate of only 8%. Systemic treatment, including chemotherapy, immunotherapy, and targeted therapy, has historically shown limited efficacy. The first (and so far only) systemic treatment to demonstrate an improvement in overall survival is tebentafusp, which is now approved for treatment of patients with metastatic or unresectable uveal melanoma and an HLA-A*02:01 genotype. Liver-directed therapies include surgical resection, radioembolization, chemoembolization, immune-embolization, isolated hepatic perfusion, and percutaneous hepatic perfusion. This review discusses the clinical background of uveal melanoma and liver metastasis, the efficacy of systemic and locoregional treatment options, and the promising development of combining locoregional liver-directed treatment with systemic treatment.<\/jats:p>","DOI":"10.1093\/bjs\/znaf130","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T08:04:16Z","timestamp":1759305856000},"source":"Crossref","is-referenced-by-count":11,"title":["Management of liver metastases from uveal melanoma"],"prefix":"10.1093","volume":"112","author":[{"given":"Anne","family":"Huibers","sequence":"first","affiliation":[{"name":"Department of Surgery, Sahlgrenska University Hospital , Gothenburg ,","place":["Sweden"]},{"name":"Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg , Gothenburg ,","place":["Sweden"]},{"name":"Department of Radiology, Sahlgrenska University Hospital , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5258-291X","authenticated-orcid":false,"given":"Mark","family":"Burgmans","sequence":"additional","affiliation":[{"name":"Department of Radiology, Leiden University Medical Centre , Leiden ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Ny","sequence":"additional","affiliation":[{"name":"Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg , Gothenburg ,","place":["Sweden"]},{"name":"Department of Oncology, Sahlgrenska University Hospital , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustav","family":"St\u00e5lhammar","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience, Division of Eye and Vision, St. Erik Eye Hospital, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Kapiteijn","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Leiden University Medical Centre , Leiden ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan S","family":"Zager","sequence":"additional","affiliation":[{"name":"Department of Cutaneous Oncology, Moffitt Cancer Center , Tampa, Florida ,","place":["USA"]},{"name":"Department of Oncologic Sciences, University of South Florida Morsani College of Medicine , Tampa, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5795-0355","authenticated-orcid":false,"given":"Roger","family":"Olofsson Bagge","sequence":"additional","affiliation":[{"name":"Department of Surgery, Sahlgrenska University Hospital , Gothenburg ,","place":["Sweden"]},{"name":"Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"2025100104021503100_znaf130-B1","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2147\/OPTH.S89591","article-title":"Uveal melanoma: epidemiology, etiology, and treatment of primary disease","volume":"11","author":"Krantz","year":"2017","journal-title":"Clin Ophthalmol"},{"key":"2025100104021503100_znaf130-B2","first-page":"2579","article-title":"Incidence of uveal melanoma in Sweden from 1960 to 1998","volume":"43","author":"Bergman","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2025100104021503100_znaf130-B3","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/cncr.20866","article-title":"Incidence of noncutaneous melanomas in the U.S","volume":"103","author":"McLaughlin","year":"2005","journal-title":"Cancer"},{"key":"2025100104021503100_znaf130-B4","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/j.ophtha.2011.01.040","article-title":"Uveal melanoma: trends in incidence, treatment, and survival","volume":"118","author":"Singh","year":"2011","journal-title":"Ophthalmology"},{"key":"2025100104021503100_znaf130-B5","doi-asserted-by":"crossref","first-page":"926034","DOI":"10.3389\/fmed.2022.926034","article-title":"Trends in uveal melanoma presentation and survival during five decades: a nationwide survey of 3898 Swedish patients","volume":"9","author":"Gill","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2025100104021503100_znaf130-B6","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ajo.2025.03.002","article-title":"Increasing incidence of posterior uveal melanoma in Scandinavia 1960\u20132022: a tri-national study","volume":"274","author":"Nissen","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"2025100104021503100_znaf130-B7","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.aopr.2024.10.001","article-title":"Global incidence and prevalence in uveal melanoma","volume":"4","author":"Hou","year":"2024","journal-title":"Adv Ophthalmol Pract Res"},{"key":"2025100104021503100_znaf130-B8","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1038\/s41467-020-15606-0","article-title":"Molecular profiling of driver events in metastatic uveal melanoma","volume":"11","author":"Karlsson","year":"2020","journal-title":"Nat Commun"},{"key":"2025100104021503100_znaf130-B9","doi-asserted-by":"crossref","first-page":"386986","DOI":"10.1155\/2015\/386986","article-title":"Evidence for the role of blue light in the development of uveal melanoma","volume":"2015","author":"Logan","year":"2015","journal-title":"J Ophthalmol"},{"key":"2025100104021503100_znaf130-B10","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.ophtha.2012.01.048","article-title":"Detection and time to treatment of uveal melanoma in the United Kingdom: an evaluation of 2,384 patients","volume":"119","author":"Damato","year":"2012","journal-title":"Ophthalmology"},{"key":"2025100104021503100_znaf130-B11","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.124.12.1684","article-title":"The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V.\u00a0Twelve-year mortality rates and prognostic factors: COMS Report No. 28","volume":"124","author":"Collaborative Ocular Melanoma Study Group","year":"2006","journal-title":"Arch Ophthalmol"},{"key":"2025100104021503100_znaf130-B12","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0161-6420(02)01277-0","article-title":"The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19.","volume":"109","author":"Jampol","year":"2002","journal-title":"Ophthalmology"},{"key":"2025100104021503100_znaf130-B13","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1200\/JCO.2004.08.194","article-title":"Screening for metastasis from choroidal melanoma: the Collaborative Ocular Melanoma Study Group Report 23","volume":"22","author":"Diener-West","year":"2004","journal-title":"J Clin Oncol"},{"key":"2025100104021503100_znaf130-B14","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijrobp.2016.01.040","article-title":"Practice patterns analysis of ocular proton therapy centers: the international OPTIC survey","volume":"95","author":"Hrbacek","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025100104021503100_znaf130-B15","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41571-022-00714-1","article-title":"Advances in the clinical management of uveal melanoma","volume":"20","author":"Carvajal","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"2025100104021503100_znaf130-B16","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1016\/j.jcjo.2024.07.014","article-title":"Tailoring surveillance imaging in uveal melanoma based on individual metastatic risk.","volume":"60","author":"Hagstr\u00f6m","year":"2025","journal-title":"Canadian journal of ophthalmology. Journal canadien d'ophtalmologie"},{"key":"2025100104021503100_znaf130-B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2025.03.019","article-title":"Surveillance for metastasis in low-risk uveal melanoma patients: the need for optimization","author":"Delaney","year":"2025","journal-title":"Ophthalmology"},{"key":"2025100104021503100_znaf130-B18","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMoa1000584","article-title":"Mutations in GNA11 in uveal melanoma","volume":"363","author":"Van Raamsdonk","year":"2010","journal-title":"N Engl J Med"},{"key":"2025100104021503100_znaf130-B19","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ccell.2017.04.002","article-title":"RasGRP3 mediates MAPK pathway activation in GNAQ mutant uveal melanoma","volume":"31","author":"Chen","year":"2017","journal-title":"Cancer Cell"},{"key":"2025100104021503100_znaf130-B20","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1158\/1535-7163.MCT-12-1020","article-title":"Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death","volume":"12","author":"Ambrosini","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"2025100104021503100_znaf130-B21","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ccr.2014.04.016","article-title":"Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry","volume":"25","author":"Feng","year":"2014","journal-title":"Cancer Cell"},{"key":"2025100104021503100_znaf130-B22","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ccell.2017.12.013","article-title":"Integrative analysis identifies four molecular and clinical subsets in uveal melanoma","volume":"33","author":"Robertson","year":"2018","journal-title":"Cancer Cell"},{"key":"2025100104021503100_znaf130-B23","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1126\/science.1194472","article-title":"Frequent mutation of BAP1 in metastasizing uveal melanomas","volume":"330","author":"Harbour","year":"2010","journal-title":"Science"},{"key":"2025100104021503100_znaf130-B24","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.3390\/cancers16193407","article-title":"A clinico-genetic score incorporating disease-free intervals and chromosome 8q copy numbers: a novel prognostic marker for recurrence and survival following liver resection in patients with liver metastases of uveal melanoma","volume":"16","author":"Mariani","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2025100104021503100_znaf130-B25","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1167\/iovs.03-0538","article-title":"Very long-term prognosis of patients with malignant uveal melanoma","volume":"44","author":"Kujala","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2025100104021503100_znaf130-B26","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1001\/archopht.119.5.670","article-title":"Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS Report No. 15","volume":"119","author":"Collaborative Ocular Melanoma Study Group","year":"2001","journal-title":"Arch Ophthalmol"},{"issue":"Suppl 9","key":"2025100104021503100_znaf130-B27","doi-asserted-by":"crossref","first-page":"ix371","DOI":"10.1016\/S0923-7534(20)33695-4","article-title":"1140P\u2014Metastatic uveal melanoma: a 22 years single center experience","volume":"23","author":"Valpione","year":"2012","journal-title":"Ann Oncol"},{"key":"2025100104021503100_znaf130-B28","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1136\/bjophthalmol-2012-302323","article-title":"MRI in the detection of hepatic metastases from high-risk uveal melanoma: a prospective study in 188 patients","volume":"97","author":"Marshall","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"2025100104021503100_znaf130-B29","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1159\/000495113","article-title":"Uveal melanoma metastatic to the liver: treatment trends and outcomes","volume":"5","author":"Xu","year":"2019","journal-title":"Ocul Oncol Pathol"},{"key":"2025100104021503100_znaf130-B30","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1001\/jamaophthalmol.2018.2466","article-title":"Survival rates in patients after treatment for metastasis from uveal melanoma","volume":"136","author":"Lane","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"2025100104021503100_znaf130-B31","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1001\/jamaophthalmol.2014.5395","article-title":"International validation of the American Joint Committee on Cancer\u2019s 7th edition classification of uveal melanoma","volume":"133","author":"AJCC Ophthalmic Oncology Task Force","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"2025100104021503100_znaf130-B32","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.ophtha.2017.11.040","article-title":"Iris melanoma outcomes based on the American Joint Committee on Cancer classification (eighth edition) in 432 patients","volume":"125","author":"Shields","year":"2018","journal-title":"Ophthalmology"},{"key":"2025100104021503100_znaf130-B33","doi-asserted-by":"crossref","first-page":"7205","DOI":"10.1158\/0008-5472.CAN-04-1750","article-title":"Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death","volume":"64","author":"Onken","year":"2004","journal-title":"Cancer Res"},{"key":"2025100104021503100_znaf130-B34","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/j.ophtha.2012.02.017","article-title":"Collaborative Ocular Oncology Group Report Number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma","volume":"119","author":"Onken","year":"2012","journal-title":"Ophthalmology"},{"key":"2025100104021503100_znaf130-B35","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3390\/cancers12020477","article-title":"Multicenter external validation of the Liverpool Uveal Melanoma Prognosticator Online: an OOG collaborative study","volume":"12","author":"Cunha Rola","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2025100104021503100_znaf130-B36","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.1158\/1078-0432.CCR-08-0012","article-title":"Visualization of circulating melanoma cells in peripheral blood of patients with primary uveal melanoma","volume":"14","author":"Ulmer","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2025100104021503100_znaf130-B37","doi-asserted-by":"crossref","first-page":"856","DOI":"10.3390\/cancers11060856","article-title":"Pilot study of circulating tumor cells in early-stage and metastatic uveal melanoma","volume":"11","author":"Anand","year":"2019","journal-title":"Cancers (Basel)"},{"key":"2025100104021503100_znaf130-B38","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/sj.eye.6702322","article-title":"Identification of circulating malignant cells and its correlation with prognostic factors and treatment in uveal melanoma. A prospective longitudinal study","volume":"21","author":"Callejo","year":"2007","journal-title":"Eye (Lond)"},{"key":"2025100104021503100_znaf130-B39","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/ijc.28436","article-title":"Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma","volume":"134","author":"Bidard","year":"2014","journal-title":"Int J Cancer"},{"key":"2025100104021503100_znaf130-B40","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1755-3768.2009.01617.x","article-title":"Circulating melanoma cells in peripheral blood of patients with uveal melanoma before and after different therapies and association with prognostic parameters: a pilot study","volume":"89","author":"Suesskind","year":"2011","journal-title":"Acta Ophthalmol"},{"key":"2025100104021503100_znaf130-B41","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1002\/ijc.26031","article-title":"The seed and soil hypothesis revisited\u2014the role of tumor-stroma interactions in metastasis to different organs","volume":"128","author":"Langley","year":"2011","journal-title":"Int J Cancer"},{"key":"2025100104021503100_znaf130-B42","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1158\/1541-7786.MCR-21-0526","article-title":"Uveal melanoma exosomes induce a prometastatic microenvironment through macrophage migration inhibitory factor","volume":"20","author":"Ambrosini","year":"2022","journal-title":"Mol Cancer Res"},{"key":"2025100104021503100_znaf130-B43","doi-asserted-by":"crossref","first-page":"217531","DOI":"10.1016\/j.canlet.2025.217531","article-title":"Extracellular vesicles in uveal melanoma\u2014biological roles and diagnostic value","volume":"615","author":"Urz\u00ec","year":"2025","journal-title":"Cancer Lett"},{"key":"2025100104021503100_znaf130-B44","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.3390\/cancers16172977","article-title":"New insights into the exosome-induced migration of uveal melanoma cells and the pre-metastatic niche formation in the liver","volume":"16","author":"Ramos","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2025100104021503100_znaf130-B45","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1186\/1471-2407-14-962","article-title":"MicroRNA in exosomes isolated directly from the liver circulation in patients with metastatic uveal melanoma","volume":"14","author":"Eldh","year":"2014","journal-title":"BMC Cancer"},{"key":"2025100104021503100_znaf130-B46","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1001\/jamaophthalmol.2013.2547","article-title":"Progression of ocular melanoma metastasis to the liver: the 2012 Zimmerman lecture","volume":"131","author":"Grossniklaus","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"2025100104021503100_znaf130-B47","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.humpath.2016.07.012","article-title":"Metastatic ocular melanoma to the liver exhibits infiltrative and nodular growth patterns","volume":"57","author":"Grossniklaus","year":"2016","journal-title":"Hum Pathol"},{"key":"2025100104021503100_znaf130-B48","doi-asserted-by":"crossref","first-page":"5316","DOI":"10.3390\/cancers13215316","article-title":"Radiological patterns of uveal melanoma liver metastases in correlation to genetic status","volume":"13","author":"Yavuzyigitoglu","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025100104021503100_znaf130-B49","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/ajcp\/aqad029","article-title":"Multiorgan involvement of dormant uveal melanoma micrometastases in postmortem tissue from patients without coexisting macrometastases","volume":"160","author":"Gill","year":"2023","journal-title":"Am J Clin Pathol"},{"key":"2025100104021503100_znaf130-B50","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"key":"2025100104021503100_znaf130-B51","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1200\/JCO.2017.74.1090","article-title":"Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: a phase III, multicenter, randomized trial (SUMIT)","volume":"36","author":"Carvajal","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025100104021503100_znaf130-B52","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1038\/sj.bjc.6602586","article-title":"Phase I trial combining gemcitabine and treosulfan in advanced cutaneous and uveal melanoma patients","volume":"92","author":"Corrie","year":"2005","journal-title":"Br J Cancer"},{"key":"2025100104021503100_znaf130-B53","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/CMR.0b013e3283403ce9","article-title":"Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma","volume":"20","author":"Homsi","year":"2010","journal-title":"Melanoma Res"},{"key":"2025100104021503100_znaf130-B54","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/annonc\/mdt585","article-title":"Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial","volume":"25","author":"Leyvraz","year":"2014","journal-title":"Ann Oncol"},{"key":"2025100104021503100_znaf130-B55","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1158\/1078-0432.CCR-19-1223","article-title":"Randomized phase II trial and tumor mutational spectrum analysis from cabozantinib versus chemotherapy in metastatic uveal melanoma (alliance A091201)","volume":"26","author":"Luke","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2025100104021503100_znaf130-B56","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1634\/theoncologist.2015-0501","article-title":"Phase II trial of bevacizumab in combination with temozolomide as first-line treatment in patients with metastatic uveal melanoma","volume":"21","author":"Piperno-Neumann","year":"2016","journal-title":"Oncologist"},{"key":"2025100104021503100_znaf130-B57","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/CMR.0000000000000401","article-title":"Cisplatin, dacarbazine and vinblastine as first line chemotherapy for liver metastatic uveal melanoma in the era of immunotherapy: a single institution phase II study","volume":"27","author":"Schinzari","year":"2017","journal-title":"Melanoma Res"},{"key":"2025100104021503100_znaf130-B58","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/00008390-200506000-00010","article-title":"Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma","volume":"15","author":"Schmittel","year":"2005","journal-title":"Melanoma Res"},{"key":"2025100104021503100_znaf130-B59","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00432-004-0569-4","article-title":"Clinical evaluation of in vitro chemosensitivity testing: the example of uveal melanoma","volume":"130","author":"Terheyden","year":"2004","journal-title":"J Cancer Res Clin Oncol"},{"key":"2025100104021503100_znaf130-B60","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1001\/jama.2014.6096","article-title":"Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial","volume":"311","author":"Carvajal","year":"2014","journal-title":"JAMA"},{"key":"2025100104021503100_znaf130-B61","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/bjc.2016.419","article-title":"Phase II randomised discontinuation trial of the MET\/VEGF receptor inhibitor cabozantinib in metastatic melanoma","volume":"116","author":"Daud","year":"2017","journal-title":"Br J Cancer"},{"key":"2025100104021503100_znaf130-B62","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1158\/1078-0432.CCR-08-2243","article-title":"Overexpression of the KIT\/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate","volume":"15","author":"Hofmann","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2025100104021503100_znaf130-B63","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/CMR.0b013e328358b373","article-title":"A pilot study of sunitinib malate in patients with metastatic uveal melanoma","volume":"22","author":"Mahipal","year":"2012","journal-title":"Melanoma Res"},{"key":"2025100104021503100_znaf130-B64","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/bjc.2016.119","article-title":"Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study","volume":"115","author":"Mouriaux","year":"2016","journal-title":"Br J Cancer"},{"key":"2025100104021503100_znaf130-B65","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1158\/1535-7163.MCT-19-0098","article-title":"Genomic profiling of metastatic uveal melanoma and clinical results of a phase I study of the protein kinase C inhibitor AEB071","volume":"19","author":"Piperno-Neumann","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"2025100104021503100_znaf130-B66","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1038\/s41416-022-02133-6","article-title":"A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma","volume":"128","author":"Piperno-Neumann","year":"2023","journal-title":"Br J Cancer"},{"key":"2025100104021503100_znaf130-B67","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10637-008-9143-2","article-title":"O-Mel-Inib: a Canc\u00e9ro-p\u00f4le Nord-Ouest multicenter phase II trial of high-dose imatinib mesylate in metastatic uveal melanoma","volume":"26","author":"Penel","year":"2008","journal-title":"Invest New Drugs"},{"key":"2025100104021503100_znaf130-B68","first-page":"114009","article-title":"A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM)","volume":"202","author":"Sacco","year":"2024","journal-title":"Ann Oncol"},{"key":"2025100104021503100_znaf130-B69","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/CMR.0000000000000509","article-title":"Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma","volume":"28","author":"Shah","year":"2018","journal-title":"Melanoma Res"},{"key":"2025100104021503100_znaf130-B70","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00262-011-1089-0","article-title":"Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy","volume":"61","author":"Danielli","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"2025100104021503100_znaf130-B71","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/CMR.0000000000000175","article-title":"A phase 2 study of tremelimumab in patients with advanced uveal melanoma","volume":"25","author":"Joshua","year":"2015","journal-title":"Melanoma Res"},{"key":"2025100104021503100_znaf130-B72","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1093\/annonc\/mdt376","article-title":"Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma","volume":"24","author":"Maio","year":"2013","journal-title":"Ann Oncol"},{"key":"2025100104021503100_znaf130-B73","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.1038\/s41467-021-25332-w","article-title":"The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma","volume":"12","author":"Ny","year":"2021","journal-title":"Nat Commun"},{"key":"2025100104021503100_znaf130-B74","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.20.00605","article-title":"Nivolumab and ipilimumab in metastatic uveal melanoma: results from a single-arm phase II study","volume":"39","author":"Pelster","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025100104021503100_znaf130-B75","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.20.00550","article-title":"Nivolumab plus ipilimumab for treatment-naive metastatic uveal melanoma: an open-label, multicenter, phase II trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)","volume":"39","author":"Piulats","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025100104021503100_znaf130-B76","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s00262-019-02352-6","article-title":"Pembrolizumab as first-line treatment for metastatic uveal melanoma","volume":"68","author":"Rossi","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"2025100104021503100_znaf130-B77","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/CMR.0000000000000653","article-title":"Phase Ib\/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM)","volume":"30","author":"Rozeman","year":"2020","journal-title":"Melanoma Res"},{"key":"2025100104021503100_znaf130-B78","doi-asserted-by":"crossref","first-page":"e0118564","DOI":"10.1371\/journal.pone.0118564","article-title":"Phase II DeCOG-study of ipilimumab in pretreated and treatment-naive patients with metastatic uveal melanoma","volume":"10","author":"Zimmer","year":"2015","journal-title":"PLoS One"},{"key":"2025100104021503100_znaf130-B79","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1200\/JCO.21.01805","article-title":"Phase I study of safety, tolerability, and efficacy of tebentafusp using a step-up dosing regimen and expansion in patients with metastatic uveal melanoma","volume":"40","author":"Carvajal","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025100104021503100_znaf130-B80","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1038\/s41591-022-02015-7","article-title":"Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial","volume":"28","author":"Carvajal","year":"2022","journal-title":"Nat Med"},{"key":"2025100104021503100_znaf130-B81","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1056\/NEJMoa2304753","article-title":"Three-year overall survival with tebentafusp in metastatic uveal melanoma","volume":"389","author":"Hassel","year":"2023","journal-title":"N Engl J Med"},{"key":"2025100104021503100_znaf130-B82","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"key":"2025100104021503100_znaf130-B83","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/CJI.0000000000000558","article-title":"Immune profiling of uveal melanoma liver metastases and response to checkpoint inhibitors","volume":"48","author":"Shao","year":"2025","journal-title":"J Immunother"},{"key":"2025100104021503100_znaf130-B84","doi-asserted-by":"crossref","first-page":"e000331","DOI":"10.1136\/jitc-2019-000331","article-title":"Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study","volume":"8","author":"Najjar","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100104021503100_znaf130-B85","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/s40425-019-0800-0","article-title":"Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study","volume":"7","author":"Heppt","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2025100104021503100_znaf130-B86","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.3390\/cancers11101489","article-title":"Real-world impact of immune checkpoint inhibitors in metastatic uveal melanoma","volume":"11","author":"Bol","year":"2019","journal-title":"Cancers (Basel)"},{"key":"2025100104021503100_znaf130-B87","doi-asserted-by":"crossref","first-page":"28903","DOI":"10.18632\/oncotarget.25627","article-title":"Real world experience in low-dose ipilimumab in combination with PD-1 blockade in advanced melanoma patients","volume":"9","author":"Kirchberger","year":"2018","journal-title":"Oncotarget"},{"issue":"Suppl","key":"2025100104021503100_znaf130-B88","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1158\/1538-7445.AM2023-1035","article-title":"Abstract 1035: Early ctDNA reduction is associated with better overall survival in the Ph 3 trial of tebentafusp in previously untreated metastatic uveal melanoma","volume":"83","author":"Sullivan","year":"2023","journal-title":"Cancer Res"},{"key":"2025100104021503100_znaf130-B89","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.ejso.2009.02.016","article-title":"Surgical management of liver metastases from uveal melanoma: 16 years\u2019 experience at the Institut Curie","volume":"35","author":"Mariani","year":"2009","journal-title":"Eur J Surg Oncol"},{"key":"2025100104021503100_znaf130-B90","doi-asserted-by":"crossref","first-page":"4989","DOI":"10.1245\/s10434-025-17115-0","article-title":"Intention-to-treat analysis of hepatic resection for liver metastases from uveal melanoma: a single-center experience","volume":"32","author":"Maspero","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"2025100104021503100_znaf130-B91","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.3390\/cancers16193346","article-title":"Impact of metastatic pattern on survival in patients with posterior uveal melanoma: a retrospective cohort study","volume":"16","author":"Hindso","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2025100104021503100_znaf130-B92","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.hoc.2024.08.010","article-title":"An overview of liver directed locoregional therapies","volume":"39","author":"H\u00f6ppener","year":"2025","journal-title":"Hematol Oncol Clin North Am"},{"key":"2025100104021503100_znaf130-B93","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.hpb.2019.11.002","article-title":"Systematic review of liver directed therapy for uveal melanoma hepatic metastases","volume":"22","author":"Rowcroft","year":"2020","journal-title":"HPB (Oxford)"},{"key":"2025100104021503100_znaf130-B94","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ijrobp.2016.03.050","article-title":"Radiosensitivity differences between liver metastases based on primary histology suggest implications for clinical outcomes after stereotactic body radiation therapy","volume":"95","author":"Ahmed","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025100104021503100_znaf130-B95","doi-asserted-by":"crossref","first-page":"1406872","DOI":"10.3389\/fonc.2024.1406872","article-title":"Radiation and systemic immunotherapy for metastatic uveal melanoma: a clinical retrospective review","volume":"14","author":"Tran","year":"2024","journal-title":"Front Oncol"},{"key":"2025100104021503100_znaf130-B96","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.3390\/diagnostics13111836","article-title":"Minimally invasive treatment options for hepatic uveal melanoma metastases","volume":"13","author":"Sajan","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"2025100104021503100_znaf130-B97","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1055\/s-0040-1720948","article-title":"Locoregional therapies for the treatment of uveal melanoma hepatic metastases","volume":"37","author":"Gonsalves","year":"2020","journal-title":"Semin Intervent Radiol"},{"key":"2025100104021503100_znaf130-B98","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1053\/j.seminoncol.2010.03.014","article-title":"Locoregional management of hepatic metastasis from primary uveal melanoma","volume":"37","author":"Sato","year":"2010","journal-title":"Semin Oncol"},{"key":"2025100104021503100_znaf130-B99","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1080\/07357900802620893","article-title":"A first report of radioembolization for hepatic metastases from ocular melanoma","volume":"27","author":"Kennedy","year":"2009","journal-title":"Cancer Invest"},{"key":"2025100104021503100_znaf130-B100","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1148\/radiol.2019190199","article-title":"A prospective phase II trial of radioembolization for treatment of uveal melanoma hepatic metastasis","volume":"293","author":"Gonsalves","year":"2019","journal-title":"Radiology"},{"key":"2025100104021503100_znaf130-B101","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10585-023-10234-6","article-title":"Isolated hyperthermic perfusions for cutaneous melanoma in-transit metastasis of the limb and uveal melanoma metastasis to the liver","volume":"41","author":"Huibers","year":"2023","journal-title":"Clin Exp Metastasis"},{"key":"2025100104021503100_znaf130-B102","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1200\/JCO.22.01705","article-title":"Isolated hepatic perfusion with melphalan for patients with isolated uveal melanoma liver metastases: a multicenter, randomized, open-label, phase III trial (the SCANDIUM trial)","volume":"41","author":"Olofsson Bagge","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025100104021503100_znaf130-B103","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/SLA.0000000000006255","article-title":"Survival and quality of life after isolated hepatic perfusion with melphalan as a treatment for uveal melanoma liver metastases\u2014final results from the phase III randomized controlled trial SCANDIUM","volume":"282","author":"Olofsson Bagge","year":"2024","journal-title":"Ann Surg"},{"key":"2025100104021503100_znaf130-B104","first-page":"1758","article-title":"[Extracorporeal adriamycin-removal following hepatic artery infusion: use of direct hemoperfusion combined with veno-venous bypass]","volume":"90","author":"Ku","year":"1989","journal-title":"Nihon Geka Gakkai Zasshi"},{"key":"2025100104021503100_znaf130-B105","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1200\/JCO.2005.00.927","article-title":"Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies","volume":"23","author":"Pingpank","year":"2005","journal-title":"J Clin Oncol"},{"key":"2025100104021503100_znaf130-B106","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1245\/s10434-020-08741-x","article-title":"Percutaneous hepatic perfusion with melphalan in patients with unresectable ocular melanoma metastases confined to the liver: a prospective phase II study","volume":"28","author":"Meijer","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"2025100104021503100_znaf130-B107","doi-asserted-by":"crossref","first-page":"5340","DOI":"10.1245\/s10434-024-15293-x","article-title":"Efficacy and safety of the melphalan\/hepatic delivery system in patients with unresectable metastatic uveal melanoma: results from an open-label, single-arm, multicenter phase 3 study","volume":"31","author":"Zager","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"2025100104021503100_znaf130-B108","doi-asserted-by":"crossref","first-page":"4726","DOI":"10.3390\/cancers13184726","article-title":"Meta-analysis of isolated hepatic perfusion and percutaneous hepatic perfusion as a treatment for uveal melanoma liver metastases","volume":"13","author":"Bethlehem","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025100104021503100_znaf130-B109","doi-asserted-by":"crossref","first-page":"103623","DOI":"10.1016\/j.esmoop.2024.103623","article-title":"A phase Ib randomized multicenter trial of isolated hepatic perfusion in combination with ipilimumab and nivolumab for uveal melanoma metastases (SCANDIUM II trial)","volume":"9","author":"Olofsson Bagge","year":"2024","journal-title":"ESMO Open"},{"key":"2025100104021503100_znaf130-B110","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s00270-022-03338-1","article-title":"Combining melphalan percutaneous hepatic perfusion with ipilimumab plus nivolumab in advanced uveal melanoma: first safety and efficacy data from the phase Ib part of the CHOPIN trial","volume":"46","author":"Tong","year":"2023","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"Suppl","key":"2025100104021503100_znaf130-B111","doi-asserted-by":"crossref","first-page":"10025","DOI":"10.1200\/JCO.2020.38.15_suppl.10025","article-title":"Initial report of treatment of uveal melanoma with hepatic metastases with yttrium90 internal radiation followed by ipilimumab and nivolumab","volume":"38","author":"Minor","year":"2020","journal-title":"J Clin Oncol"},{"issue":"Suppl. 16","key":"2025100104021503100_znaf130-B112","doi-asserted-by":"crossref","first-page":"9511","DOI":"10.1200\/JCO.2022.40.16_suppl.9511","article-title":"First interim analysis of the SirTac trial: a randomized phase II study of SIRT and DSM-TACE in patients with liver metastases from uveal melanoma [abstract]","volume":"40","author":"Peuker","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025100104021503100_znaf130-B113","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jvir.2014.11.037","article-title":"Double-blinded, randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor in uveal melanoma with hepatic metastases","volume":"26","author":"Valsecchi","year":"2015","journal-title":"J Vasc Interv Radiol"},{"key":"2025100104021503100_znaf130-B114","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000006720","article-title":"The #HOPE4LIVER single-arm pivotal trial for histotripsy of primary and metastatic liver tumors: 1-year update of clinical outcomes","author":"Ziemlewicz","year":"2025","journal-title":"Ann Surg"},{"key":"2025100104021503100_znaf130-B115","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.jvir.2014.01.028","article-title":"Irreversible electroporation for nonthermal tumor ablation in the clinical setting: a systematic review of safety and efficacy","volume":"25","author":"Scheffer","year":"2014","journal-title":"J Vasc Interv Radiol"},{"issue":"Suppl","key":"2025100104021503100_znaf130-B116","doi-asserted-by":"crossref","first-page":"9511","DOI":"10.1200\/JCO.2024.42.16_suppl.9511","article-title":"Safety, efficacy, and biomarker results from an open-label, multicenter, phase 1 study of RP2 alone or combined with nivolumab in a cohort of patients with uveal melanoma","volume":"42","author":"Sacco","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025100104021503100_znaf130-B117","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1038\/s41416-022-01723-8","article-title":"Future perspectives of uveal melanoma blood based biomarkers","volume":"126","author":"Beasley","year":"2022","journal-title":"Br J Cancer"},{"key":"2025100104021503100_znaf130-B118","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3389\/fphar.2016.00424","article-title":"Increased levels of miRNA-146a in serum and histologic samples of patients with uveal melanoma","volume":"7","author":"Russo","year":"2016","journal-title":"Front Pharmacol"},{"key":"2025100104021503100_znaf130-B119","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1080\/15384047.2015.1046021","article-title":"miRNA profiling in vitreous humor, vitreal exosomes and serum from uveal melanoma patients: pathological and diagnostic implications","volume":"16","author":"Ragusa","year":"2015","journal-title":"Cancer Biol Ther"}],"container-title":["British Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjs\/article-pdf\/112\/8\/znaf130\/63955861\/znaf130.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjs\/article-pdf\/112\/8\/znaf130\/63955861\/znaf130.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T08:04:29Z","timestamp":1759305869000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjs\/article\/doi\/10.1093\/bjs\/znaf130\/8222400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":119,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,5]]},"published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/bjs\/znaf130","relation":{},"ISSN":["0007-1323","1365-2168"],"issn-type":[{"value":"0007-1323","type":"print"},{"value":"1365-2168","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,8,1]]},"article-number":"znaf130"}}